Pfizer and BioNTech announced Thursday that their vaccine to prevent influenza and COVID-19 elicited a strong immune response against the virus strain in early to mid-stage trials. (Joanna Geron, Reuters)
Estimated reading time: less than 1 minute
NEW YORK – Pfizer and German partner BioNTech announced Thursday that their vaccine to prevent influenza and COVID-19 elicited a strong immune response against the virus strain in early to mid-stage trials.
The companies said they plan to begin late-stage trials in the coming months.
“This vaccine has the potential to reduce the impact of two respiratory illnesses with a single injection, potentially simplifying the delivery of immunizations,” Annalisa Anderson, Pfizer’s head of vaccine research and development, said in a statement. “There is,” he said.
The trial compared the vaccine candidate to a licensed influenza vaccine and the company’s latest coronavirus vaccine administered during the same visit.
The companies said trial data showed the influenza-COVID-19 vaccine produced strong immune responses against influenza A, influenza B, and SARS-CoV-2 strains.
